Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Ferrisat vs Placebo in Anemia Associated to Inflammatory Bowel Disease During Anti-TNF Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 18 years~* Crohn's disease or Ulcerative Colitis defined according to the usual endoscopic, histological, and radiological criteria~* Under anti-TNF therapy or indication for starting an anti-TNF therapy~* Anemia defined according to World Health Organization (Hemoglobin under 13g/dl for man and Hemoglobin under 12g/dl for woman)~* Iron deficiency anemia defined as:~* Ferritinemia under 100 if C-Reactive Protein under normal value OR - Ferritinemia between 30 and 100 if C-Reactive Protein above normal value~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferrisat (Type: ACTIVE_COMPARATOR): Infusion of Ferrisat (50mg/ml) at inclusion under usual practices
- Placebo (Type: PLACEBO_COMPARATOR): Infusion of placebo at inclusion visit

Based on this trial design, predict the completion outcome and termination type (if applicable).